When he was 38, with a wife and 7-month-old at home, Gluck learned he had multiple myeloma, a cancer of the plasma cells that causes damage to bones, kidneys, and the immune system.

Survival in multiple myeloma has almost tripled since the mid-1990s, from about 3 years with conventional therapy to now 8-10 years with high-dose chemotherapy supported by autologous stem cell ...

Like treatments for many other cancers, treatments for multiple myeloma come with a high price. The drugs are “hideously expensive,” Dr. June said, costing more than $100,000 a year.

Darzalex as monotherapy was investigated in two main studies involving multiple myeloma patients whose disease relapsed after, or was refractory to, at least two previous treatments, including a ...

Source Reference: Xia J, et al "Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm ...

4. Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2024;390:301-313.

Existing risk stratification models for multiple myeloma characterize patients as "high" or "low" risk based on measures of tumor burden. These models do not include genetic factors.

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation antigen (BCMA) receptor. It received accelerated approval in 2022 for ...

Multiple myeloma is becoming an increasing global burden. In 2022, there were an estimated 188,000 new cases and 121,000 deaths worldwide.

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the approval is for patients with relapsed or refractory multiple myeloma who ...

The Spanish Society of Hematology and Hemotherapy (SEHH) held its ninth “HematoAvanza” Outreach Conference at the Pazo de San Lorenzo in Santiago, Spain. The event brought together ...